Detalles de la búsqueda
1.
Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks.
J Allergy Clin Immunol
; 153(2): 479-486.e4, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37866460
2.
Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria.
J Allergy Clin Immunol
; 150(6): 1498-1506.e2, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36096203
3.
Sequential knockoffs for continuous and categorical predictors: With application to a large psoriatic arthritis clinical trial pool.
Stat Med
; 40(14): 3313-3328, 2021 06 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-33899260
4.
Advancing data science in drug development through an innovative computational framework for data sharing and statistical analysis.
BMC Med Res Methodol
; 21(1): 250, 2021 11 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-34773974
5.
Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1.
BMC Musculoskelet Disord
; 22(1): 1037, 2021 Dec 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-34903218
6.
Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J).
Mod Rheumatol
; 30(1): 132-140, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30334633
7.
Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III Study.
Arthritis Rheumatol
; 73(1): 110-120, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32770640
8.
Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT.
Arthritis Res Ther
; 23(1): 231, 2021 09 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34481517
9.
Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5.
Chin Med J (Engl)
; 133(21): 2521-2531, 2020 Nov 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32925287
10.
Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study.
Rheumatol Ther
; 4(2): 475-488, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29138986
Resultados
1 -
10
de 10
1
Próxima >
>>